Why the study?
Does intravenous magnesium improve outcomes in patients with torsade de pointes or digitalis-induced tachycardias?
Does intravenous magnesium improve outcomes in patients with torsade de pointes or digitalis-induced tachycardias?
Intravenous magnesium is the treatment of choice for torsade de pointes associated with acquired long QT syndrome and is useful in digitalis-induced tachycardias.
Answers are grounded in this paper and cite their sources.
Supports magnesium as preferred for torsades in acquired LQTS; leaves open definitive role in digitalis-induced tachycardias.
Magnesium is an essential transmembrane and intracellular modulator of the electrical activity of cardiac cells. This review provides an up-to-date consideration of the cellular and clinical electrophysiological role of magnesium. This ubiquitous element seems to be important from both the theoretical and clinical point of view, because magnesium salts (MgSO4, MgCl2) administered intravenously are particularly effective in those arrhythmias in which the mechanism involves early or delayed after depolarization-induced triggered activity. The authors share the view that I.V. magnesium is the drug of choice in "torsade de pointes" ventricular tachycardia accompanying acquired long QT/QTU syndrome. It is complementary therapeutic agent in digitalis-induced tachycardias. Further studies are needed to elucidate magnesium's mode of action and efficacy in other types of clinical tachyarrhythmias.
No takes yet. Share an insight, caveat, or question.
Fazekas et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: